Company Overview
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals' post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024. Lifeward Ltd. was incorporated in 2001 and is based in Yokneam Illit, Israel.
Recent Developments
- Dec 2025 Revenue of $1.40M (-17.6% YoY); net profit $-19.91M.
- Trailing 12 Months Year-on-year growth — revenue +15.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -1.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -1.04% |
| 1 Year: | 15.70% |
Stock Price Performance
| 1 Year: | -13.99% |
| 6 Months: | +22.11% |
| 3 Months: | +6.02% |
| 1 Month: | -3.71% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)50.91 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -1.0% CAGR over 5 years.
- Trading 25.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LFWD Lifeward Ltd. PHARMA | 7.40 | -0.50 | $20.96M | 0.00% | - | - | -1.04% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 191.00K | - | - | 123.00K | - | - | 128.00K | - | - | 489.00K | - | - | 500.00K | - | - | 443.00K |
| Gross Profit | 33.00K | 60.00K | 87.00K | 493.00K | 85.00K | 290.00K | 1.05M | 741.00K | 708.00K | 682.00K | 767.00K | 762.00K | 926.00K | 435.00K | 649.00K | 373.00K | 1.02M | 392.00K | 707.00K | 727.00K | 1.14M | 265.00K | 746.00K | 221.00K | 571.00K | 576.00K | 863.00K | 1.40M | 2.76M | 2.22M | 2.12M | 2.51M | 2.71M | 1.34M |
| Operating Income | -5.52M | -5.84M | -6.30M | -6.42M | -8.59M | -7.40M | -5.66M | -5.37M | -5.35M | -5.84M | -5.28M | -4.12M | -3.58M | -4.24M | -3.03M | -3.60M | -2.55M | -3.07M | -3.02M | -3.14M | -2.66M | -4.29M | -4.38M | -5.43M | -4.38M | -5.16M | -7.94M | -6.50M | -4.44M | -3.17M | -4.85M | -6.56M | -3.14M | -10.34M |
| Net Income | -5.71M | -5.81M | -6.39M | -6.92M | -9.12M | -7.92M | -6.40M | -6.31M | -5.85M | -6.33M | -5.80M | -4.53M | -4.00M | -4.59M | -3.39M | -3.84M | -2.85M | -3.34M | -3.06M | -3.14M | -2.67M | -4.35M | -4.45M | -5.46M | -4.32M | -4.64M | -7.53M | -6.28M | -4.30M | -3.08M | -4.83M | -6.56M | -3.17M | -10.79M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.07 | -0.06 | -0.07 | -0.07 | -0.09 | -0.51 | -0.55 | -0.88 | -0.73 | -0.50 | -0.35 | -5.53 | -0.58 | -0.20 | -6.70 |
| R&D Expense | 1.54M | 1.45M | 1.26M | 1.70M | 3.07M | 1.97M | 1.43M | 1.39M | 1.62M | 2.15M | 1.90M | 1.60M | 1.41M | 1.86M | 1.02M | 985.00K | 954.00K | 756.00K | 795.00K | 810.00K | 638.00K | 907.00K | 956.00K | 1.06M | 752.00K | 816.00K | 1.26M | 1.29M | 1.21M | 998.00K | 918.00K | 767.00K | 721.00K | 5.84M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.59M | 3.95M | 3.75M | 5.87M | 135.00K | 6.54M | 4.87M | 330.00K | 432.00K | 352.00K | 435.00K | 1.70M | 1.40M |
| Gross Profit | -429.00K | -621.00K | 214.00K | 736.00K | 3.10M | 2.83M | 2.73M | 2.19M | 2.90M | 1.91M | 4.45M | 8.22M | 8.43M |
| Operating Income | -8.74M | -19.93M | -25.17M | -30.44M | -21.99M | -19.21M | -14.05M | -12.00M | -12.65M | -19.10M | -23.61M | -29.35M | -19.67M |
| Net Income | -12.18M | -21.67M | -25.41M | -32.50M | -24.72M | -21.68M | -15.55M | -12.98M | -12.74M | -19.57M | -22.13M | -28.94M | -19.91M |
| Diluted EPS | - | - | - | - | - | - | - | -0.82 | -0.27 | -2.20 | -31.13 | -39.96 | -17.16 |
| R&D Expense | 2.46M | 8.56M | 5.94M | 9.03M | 6.04M | 7.35M | 5.35M | 3.46M | 2.94M | 4.03M | 4.15M | 4.62M | 3.25M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 47.66M | 25.57M | 31.76M | 22.86M | 14.96M | 24.37M | 28.07M | 94.75M | 74.24M | 63.19M | 30.49M | 22.90M |
| Total Equity | -2.26M | 5.63M | 43.85M | 20.92M | 8.26M | 3.71M | 1.95M | 10.78M | 21.77M | 89.38M | 68.17M | 46.51M | 18.85M | 8.41M |
| Cash & Equivalents | 769.00K | 8.86M | 41.83M | 17.87M | 23.68M | 14.57M | 9.55M | 16.25M | 20.35M | 88.34M | 67.90M | 28.08M | 6.75M | 2.17M |
| Long Term Debt | - | - | - | 0 | 10.52M | 8.91M | 6.96M | 1.53M | - | - | - | - | - | - |
| Total Liabilities | - | - | 3.81M | 4.65M | 23.50M | 19.16M | 13.02M | 13.59M | 6.29M | 5.37M | 6.07M | 16.68M | 11.64M | 14.49M |
| Current Liabilities | - | - | 3.57M | 4.34M | 12.40M | 9.73M | 5.38M | 10.17M | 4.67M | 4.04M | 4.78M | 11.79M | 10.22M | 12.04M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -26.75M | -22.46M | -14.77M | -14.81M | -12.59M | -11.47M | -17.89M | -20.67M | -21.72M | -16.83M |
| Investing Cash Flow | - | - | - | -437.00K | -21.00K | -13.00K | -22.00K | -73.00K | -47.00K | -25.00K | -18.15M | 0 | -16.00K |
| Financing Cash Flow | - | - | - | 33.78M | 13.41M | 9.71M | 21.48M | 16.72M | 79.51M | -2.50M | -992.00K | 0 | 12.20M |
| Capital Expenditure | -187.00K | -169.00K | -584.00K | -452.00K | -21.00K | -13.00K | -22.00K | -73.00K | -47.00K | -25.00K | -81.00K | -0 | -16.00K |
| Free Cash Flow | - | - | - | -27.20M | -22.48M | -14.79M | -14.84M | -12.66M | -11.52M | -17.92M | -20.75M | -21.72M | -16.84M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -27.0% | -15.7% | 5.7% | 12.5% | 2,297.0% | 43.2% | 55.9% | 663.3% | 672.0% | 541.2% | 1,023.7% | 483.3% | 602.0% |
| Operating Margin % | -550.7% | -504.3% | -672.0% | -518.7% | -16,290.4% | -293.6% | -288.3% | -3,637.6% | -2,929.4% | -5,426.7% | -5,428.0% | -1,726.3% | -1,405.3% |
| Net Margin % | -766.8% | -548.4% | -678.5% | -553.8% | -18,308.9% | -331.2% | -319.1% | -3,932.1% | -2,948.1% | -5,559.4% | -5,088.0% | -1,702.5% | -1,422.4% |
| ROE % | -216.2% | -49.4% | -121.5% | -393.5% | -666.8% | -1,114.4% | -144.3% | -59.6% | -14.2% | -28.7% | -47.6% | -153.5% | -236.8% |
| ROCE % | - | -45.2% | -118.6% | -157.2% | -167.4% | -200.6% | -98.9% | -51.3% | -14.0% | -27.5% | -45.9% | -144.8% | -181.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 0.64% | 18.06K | $125.00K |
| 2 | Renaissance Technologies, LLC | 0.40% | 11.33K | $78.38K |
| 3 | UBS Group AG | 0.08% | 2.15K | $14.89K |
| 4 | SBI Securities Co., Ltd. | 0.01% | 196 | $1.36K |
| 5 | Morgan Stanley | 0.01% | 274 | $1.90K |
| 6 | Motiv8 Investments LLC | - | 3 | $20 |
| 7 | Caitong International Asset Management Co., Ltd | - | 4 | $27 |
| 8 | National Bank of Canada/FI/ | - | 11 | $76 |
| 9 | Osaic Holdings Inc. | - | 107 | $740 |
| 10 | Royal Bank of Canada | - | 50 | $346 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LFWD
Rehabilitation products are at the center of Lifeward's expansion plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNcWEzUFNUbi1NUmpiaXgyVVZHSUI3YUxxcHN0cXhCSVZ4NjFjdkVzVVdLUlcxbC1fWERsWEJITFdXeDlSQUdSY2piSGtsNG5pdXNZN0I3YjdzZDVLYS1UV19kRWF0VDhzeTJzd1pmSFhfak1lV1pmTWRtbEtCTGQ1VnFXaWNpSzAxTVZhd3…
How (LFWD) Movements Inform Risk Allocation Models - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxOWTJ2akJpTElUbWs5bWdCRG5NOVc0elFaZDRSVUZ0d2tQR0VXSEZqSVlLX1Q4LXpYSkpGX2RzMnBtLXhQVzItSlVlRWNFa1BmUlJpVnQ0ejIzSGl1ekhnbzFJdmYxYXJFX0NnM3FLcW1nMWI2RkhvODZUbEQ1TkJZMllDNml4LXktckNOeD…
Oramed backs exoskeleton maker Lifeward (NASDAQ: LFWD) in milestone-based funding deal - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPRFNlRl9oaFVoSkdUNzJMUHY5Y2Jlb3dTVE1xY29INkNBQ2JrQWl4eW1fSk9rdVZrekh6WU14TFNRbXl2djdEdmE0TUZkYmZoLVVObWN1bWlfVTdXMjk2U3Fja0psX2lEYTZ4d01DUlJZb1pBX1ZkNFNzUUJkXzZEU1h5M2JSWndsY0VkRm…
Earnings To Watch: Lifeward Ltd (LFWD) Q2 2026 -- GF Value Sees 185% Upside - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNbGJVMURmb0ROdlFTOWl4a194OVI2RkFscmJZWVRCMTFpQ1NjcVR1cDdkclFkWThjYzIxOHk3T3BEOE5ScmJlcDNqT2c0MUVKSUN2MFNaSEhyWDdrbDlwTVA3Qml5Y01lMF9IQmpsQl95dGJ1cE1pZFFZMHRwbzJsNGxna2VXQjRYek43eH…
LFWD Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1ES0tOOTkyN1pqMklJX1ZzMGd3d2d3cV95dEx6LWdjS2tIT1d5aV9Wamh0UVJMVTF6WUZsWW1wejA2ZTRVVGNfNno2UURjU2hGWUhtaTJtekR4cHNVMkpoVUtwQ1lJYTh0MVh0RWU1eFpUMnpIM0U4SFRB?oc=5" target="_blank">LFW…
Lifeward Announces Major CEO and CFO Leadership Changes - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNZWVwSHpkNWtKWjZKN2x5UHJrOTBRRU5EYm1VcjdYdjJLMnJrc3I0dDNLYTdoSWFleXVjc09xeGxFeGt4Z0RzakhaRDJxRW9lRXFhRlVNelVBa09ZbGRFT1J3TEhSVVJHVnpGR1phSDZKb2dTMVQtMmtRVnRIMXQ3Sm1qdm1qQzIwUk40Qn…
LFWD — Frequently Asked Questions
What is the current share price of Lifeward Ltd. (LFWD)?
As of 2026-09-19 21:16 PDT, Lifeward Ltd. (LFWD) trades at $7.40 on NasdaqCM. Its 52-week range is $4.60 to $9.94.
What is the market capitalisation of LFWD?
Lifeward Ltd. (LFWD) has a market capitalisation of $20.96M on NasdaqCM.
What is the P/E ratio of LFWD?
LFWD trades at a trailing price-to-earnings (P/E) ratio of -0.50. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.60.
Is LFWD a good stock to buy?
This page provides a data-driven analysis of Lifeward Ltd. (LFWD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.